Company Overview and News
(Reuters) - U.S. regional bank PNC Financial Services Group Inc (PNC.N) on Friday reported disappointing quarterly loan growth and said it expected only a small improvement in lending for the final three months of the year, sending its shares down 5 percent.
PNC PNUCL PNCFO
Oct 12 (Reuters) - U.S. regional bank PNC Financial Services Group Inc said on Friday it expected loan growth to improve slightly in the fourth quarter, while net interest income and fee income are expected to rise in low single digits.
PNC PNUCL PNCFO
Driven by stellar revenues, PNC Financial (PNC - Free Report) delivered a positive earnings surprise of 3.3% in third-quarter 2018. Earnings per share of $2.82 beat the Zacks Consensus Estimate of $2.73. Moreover, the bottom line reflected a 30.6% jump from the prior-year figure. Continued easing of pressure on net interest margin led to higher net interest income during the reported quarter. Though mortgage banking revenues declined, overall non-interest income witnessed year-over-year growth.
BAC USB CBSH BAC CBSHP PNC PNUCL PNCFO CBCB
(Reuters) - PNC Financial Services Group Inc (PNC.N) beat analysts’ estimates for quarterly profit on Friday but loan growth at the U.S. regional bank was sluggish, sending its shares down 3.5 percent in morning trading.
PNC PNUCL PNCFO
Have you been eager to see how The PNC Financial Services Group, Inc. (PNC - Free Report) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Pennsylvania-based money center bank’s earnings release this morning: An Earnings Beat PNC Financial came out with earnings per share of $2.82, easily beating the Zacks Consensus Estimate of $2.73. Results were aided by increased net interest income and non-interest income, partially offset by higher expenses.
WFC WFCNP LRCX PNCFO ADBE PNC PNUCL
(Reuters) - U.S. regional bank PNC Financial Services Group Inc (PNC.N) beat analysts’ estimates for quarterly profit on Friday, but reported a 6 percent rise in operating expenses as it invested in marketing and retail banking.
PNC PNUCL PNCFO
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / PNC Financial Services Group, Inc. (NYSE: PNC) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 12, 2018 at 9:30 AM Eastern Time.
PNC PNUCL PNCFO ISDR
The third-quarter 2018 earnings season is already round the corner with big names — JPMorgan (JPM - Free Report) , Wells Fargo (WFC - Free Report) , Citigroup (C - Free Report) and PNC Financial (PNC - Free Report) — all reporting financial numbers tomorrow, before the opening bell. After an impressive first-half 2018 performance driven by significant volatility, client activity remained low in the third quarter.
WFC WFCNP POOL C PNCFO PNC PNUCL
The broad markets pulled back from their all-time highs to close out the past week, but this could present a nice buying opportunity ahead of the third-quarter earnings reporting season. 24/7 Wall St. has put together a preview of some of the major companies posting their quarterly results this week.
WFCNP WBA DAL WFC C PNCFO JPM CGBBW PNC PNUCL TRI
Over the last five trading days, major banks rallied on rising bond yields. The 30-year bond yield climbed to 3.320%, the highest since September 2014, as its price fell. Further, 10-year Treasury note yield increased to 3.2%, reaching its highest level since July 2011. Rising interest rates and bond yields drive banks’ net internet margins, which are expected to improve profitability in the quarters ahead.
WFCNP FRC BAC USB WFC BAC C PNCFO YY OZK PNC PNUCL
The September employment report will give the Federal Reserve more confidence in their current policy to raise short-term interest rates at a steady pace of a quarter-point every three months, economists said.
PNC PNUCL PNCFO
NEW YORK, Oct 1 (Reuters) - PNC Bank, a large lender in the eastern United States, has a new strategy for expanding into additional U.S. markets, digital-only savings accounts that pay high rates to attract customers and deposits that are accompanied by a carefully limited number of branches.
C PNCFO CGBBW PNC PNUCL
On Sep 28, we issued an updated research report on The PNC Financial Services Group (PNC - Free Report) . The company’s cost-containment efforts to drive operational efficiency along with steady loan and deposit growth indicate its upside potential. However, lack of loan diversification remains a concern.
MBIN PNCFO FFIN FMBH PNC PNUCL FSLR RPM FMAO MBNC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET